公开(公告)号：US20180318392A1

公开(公告)日：2018-11-08

申请号：US15773498

申请日：2016-11-04

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Christopher DALY ,  Samuel DAVIS

IPC: A61K38/18 ,  A61P7/04 ,  G01N33/86 ,  C07K14/515

CPC classification number: A61K38/1891 ,  A61P7/04 ,  C07K14/515 ,  C07K2319/30 ,  G01N33/86

Abstract: The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1-Fc-F1 or AngF2-Fc-F2.

公开(公告)号：US20130129722A1

公开(公告)日：2013-05-23

申请号：US13747728

申请日：2013-01-23

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Israel LOWY ,  Gavin THURSTON ,  Christopher DALY

IPC: C07K16/22 ,  A61K38/16 ,  A61K39/395

CPC classification number: C07K16/22 ,  A61K31/513 ,  A61K38/1866 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

公开(公告)号：US20240247069A1

公开(公告)日：2024-07-25

申请号：US18412280

申请日：2024-01-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yan YANG ,  Naga Suhasini AVVARU ,  Christopher DALY ,  Yang SHEN ,  Chia-Yang LIN

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622

Abstract: The present disclosure relates to molecules capable of binding to FGFR3 and methods of use thereof.

公开(公告)号：US20240158515A1

公开(公告)日：2024-05-16

申请号：US18509136

申请日：2023-11-14

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yan YANG ,  Christopher DALY ,  William OLSON ,  Tammy T. HUANG ,  Drew DUDGEON ,  Robert BABB

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention provides antibodies that bind specifically to FGFR3 and methods for treating or preventing cancer, such as bladder cancer.

公开(公告)号：US20130344093A1

公开(公告)日：2013-12-26

申请号：US13925923

申请日：2013-06-25

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Christopher DALY ,  Gavin THURSTON ,  Nicholas J. PAPADOPOULOS

IPC: A61K39/395

CPC classification number: A61K39/39558 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.

公开(公告)号：US20130084297A1

公开(公告)日：2013-04-04

申请号：US13623885

申请日：2012-09-21

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Christopher DALY ,  Douglas MacDONALD ,  Xunbao DUAN

IPC: C07K16/40 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K39/39558 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract translation: 本发明提供了结合ErbB3的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人ErbB3结合的完全人抗体。 在某些实施方案中，本发明的抗体阻断ErbB3与ErbB3配体如神经调节蛋白1的相互作用。本发明的抗体可用于治疗各种癌症。